Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas.
about
Current and future trials of targeted therapies in cutaneous melanomaDrug delivery nanoparticles in skin cancersCaprylate-conjugated Cisplatin for the development of novel liposomal formulation.Topical delivery of DNA oligonucleotide to induce p53 generation in the skin via thymidine dinucleotide (pTT)-encapsulated liposomal carrier.Etoposide incorporated into camel milk phospholipids liposomes shows increased activity against fibrosarcoma in a mouse modelCoadministration of doxorubicin and etoposide loaded in camel milk phospholipids liposomes showed increased antitumor activity in a murine model.Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluationNovel therapeutic mechanisms determine the effectiveness of lipid-core nanocapsules on melanoma models.Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells.Engineering nanomedicines for improved melanoma therapy: progress and promises.Climacostol reduces tumour progression in a mouse model of melanoma via the p53-dependent intrinsic apoptotic programme.Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.Towards new therapeutic approaches for malignant melanoma.Advances in nanotechnology-based delivery systems for curcumin.Metal ion-assisted drug-loading model for novel delivery system of cisplatin solid lipid nanoparticles with improving loading efficiency and sustained release.Preparation and characterization of cisplatin magnetic solid lipid nanoparticles (MSLNs): effects of loading procedures of Fe3O4 nanoparticles.Camptothecin-Loaded Liposomes with α-Melanocyte-Stimulating Hormone Enhance Cytotoxicity Toward and Cellular Uptake by Melanomas: An Application of Nanomedicine on Natural Product.Delivery of cisplatin from Pluronic co-polymer systems: liposome inclusion and alginate coupling.Amadori-glycated phosphatidylethanolamine enhances the physical stability and selective targeting ability of liposomes.
P2860
Q27022355-DFE357E8-65CE-4E1F-B455-54F8463F3721Q28390405-50CF11D7-D387-43D6-8569-D61D50CD1B72Q33962533-DB5CDB32-FFBF-4536-BA97-8D0C999D31F0Q34135616-D64276D9-E3AF-4FEB-BD19-6BA1633428B0Q35187801-668A7318-1239-4D6A-BB49-FB75FD4F5ADCQ35491314-932B73E5-4C6D-47D9-BB94-DF1CE9465AF9Q35597041-BF31307E-573F-452E-8A1F-FFE7E269C5FBQ36766846-E4C480E8-BE42-4DAE-8DBC-B08A43DD4675Q36900701-93C4CB04-7FCC-4FBD-A57C-CDD5BAD56238Q36936646-706F6B29-8F18-4D24-B10A-84E8D9ED5ED6Q36974284-14FCE145-BC8E-4E5D-A962-03E95698DB71Q37745182-533257D2-634C-42E8-9381-407DD3D00E8CQ37951743-7B064410-DC52-42C7-9D79-491AA62DE1C3Q38030643-AF685CEA-DA33-42FD-9E9B-41CB93B3B971Q38775427-B7EF96FF-1381-486B-AD34-829CA4278C23Q38961668-451C2FA2-9A43-4B88-BDC5-28B1C73A7B7FQ41813636-DA0696DC-596A-45D7-B4E7-B44671983F42Q46005280-05844501-6D92-4518-B49B-2CDCF4420FE0Q52668109-C950BF40-0D75-4C64-A077-5573CAA0F07B
P2860
Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Cisplatin encapsulated in phos ...... ccumulation against melanomas.
@ast
Cisplatin encapsulated in phos ...... ccumulation against melanomas.
@en
type
label
Cisplatin encapsulated in phos ...... ccumulation against melanomas.
@ast
Cisplatin encapsulated in phos ...... ccumulation against melanomas.
@en
prefLabel
Cisplatin encapsulated in phos ...... ccumulation against melanomas.
@ast
Cisplatin encapsulated in phos ...... ccumulation against melanomas.
@en
P2093
P1476
Cisplatin encapsulated in phos ...... ccumulation against melanomas.
@en
P2093
Jia-You Fang
Shu-Chiou Hua
Tsong-Long Hwang
Woan-Ruoh Lee
P356
10.1016/J.JDERMSCI.2006.12.011
P577
2007-01-30T00:00:00Z